stockrowVeru Inc.
VERU Healthcare Biotechnology
Veru Inc.’s revenue for fiscal 2024 (year ended September 2024) was $16.9 million, up 3.62% from fiscal 2023.
- EPS
- +40.0%
- Free cash flow
- +0.27%
Quarter to June 2026, against a year earlier
Follow VERU
Alert me
Veru Inc. (VERU) EV/Sales
As of 6 November 2026, Veru Inc. (VERU) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from 0.0× (January 2024) to 34.5× (August 2022); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 4.4× | 28.18% |
| FY2023 | 3.4× | (84.15%) |
| FY2022 | 21.5× | 147.80% |
| FY2021 | 8.7× | 118.03% |
| FY2020 | 4.0× | (8.80%) |
| FY2019 | 4.4× | (9.16%) |
| FY2018 | 4.8× | (12.97%) |
| FY2017 | 5.5× | 274.71% |
| FY2016 | 1.5× | 17.19% |
| FY2015 | 1.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 4.4× | (34.98%) |
| Jun 2024 | 6.7× | 51.03% |
| Mar 2024 | 4.4× | 53.17% |
| Dec 2023 | 2.9× | (14.79%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PMN Promis Neurosciences compare | −5,573× |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NNVC NanoViricides, Inc. compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| VERU Veru Inc. | 1.4× |
| PTHS Pelthos Therapeutics Inc. compare | 1.9× |
| GRCE Grace Therapeutics, Inc. compare | 106× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)